Citigroup Rates ResMed (RMD) buy, $270 Price Target

Citigroup maintains its buy rating on RMD, setting a $270 price target, a 38.62% upside from the current price.

By TradeTexts Research Desk · Published Jun 15, 2026, 2:01 PM EDT · Updated Jun 16, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Citigroup rated ResMed Inc. ($RMD) "buy" with a $270 price target on June 15, 2026.

Since the rating, $RMD is down 2.2% after 1 week, up 3.0% after 1 month and up 24.3% to date (from the $192.19 close on Jun 15, 2026).

RMD ResMed Inc.

$238.97 -1.59% year to date

Daily close · Oct 16, 2026

Key Points

Citigroup reiterated its buy rating on RMD, setting a price target of $270 on June 15, 2026.
Citigroup's $270 price target implies 38.62% upside from ResMed Inc.'s ($RMD) current $194.78 share price.
RMD shares are trading near $194.78, with institutional activity from BlackRock, Vanguard, and others.
Insider trades include sales by CEO Michael Farrell and a rating consensus from analysts.

Get $RMD trade alerts by text

We text you when insiders, Congress or big funds trade $RMD. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated ResMed Inc. alert may contain errors. Disclosures

On June 15, 2026, Citigroup reiterated its buy rating on RMD, setting a price target of $270. This analysis was led by Laura Sutcliffe, who maintained a positive outlook on the stock. Shares of RMD are currently trading around $194.78.

Other Institutional Activity in RMD

A number of major institutional investors have been active in RMD. BlackRock, Inc. reduced its holdings by 254,629 shares, ending with about 12.1 million shares valued at approximately $2.71 billion. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both initiated positions, each holding 9.5 million and 7.9 million shares, respectively, worth over $2.1 billion and $1.77 billion. Meanwhile, State Street Corp slightly increased its stake by 17,760 shares, now holding 6.6 million shares valued at about $1.49 billion.

ResMed Inc. Stock Down 13.4%

Shares of RMD are trading near $194.78. The stock has seen varied institutional activity, with some funds reducing and others adding to their positions. The broader analyst consensus remains positive, with multiple buy ratings and a range of price targets.

12-month forecast

$RMD price target

ResMed Inc. daily closes and this analyst's $270 target. Not advice.

Insider Buying and Selling at ResMed Inc.

RMD has seen insider activity recently. On June 8, 2026, Michael Farrell, the Chairman and CEO, made a planned sale of 4,991 shares at an average price of $193.96. On the same day, Farrell also purchased 4,991 shares at $146.34, indicating varied strategic moves. Michael Rider, Global General Counsel, sold 269 shares at $190.57 on June 1, 2026.

Analysts Set New Price Targets

On June 15, 2026, Citigroup maintained its buy rating on RMD with a price target of $270. RBC Capital also maintained a buy rating on May 1, 2026, with a target of $321. Wells Fargo kept a hold rating with a $227 target on the same date. The broader analyst consensus suggests a positive outlook, with several firms maintaining buy ratings and a range of price targets.

Bottom Line

Citigroup's reiteration of its buy rating on RMD, along with a $270 price target, reflects continued confidence in the company's prospects. Investors keep a close eye on such ratings as they provide insights into how top analysts view the stock's potential. While insider sales and varied institutional activity can influence perceptions, the overall analyst consensus remains positive.